Article
20 Apr 2026
FDA Clarifies Policies For Pharmacy Compounders Of GLP-1 Products
AUTHORS CONTENT
Article
16 Apr 2026
FDA To Consider Lifting Restrictions On Numerous Compounded Peptides
Article
01 Apr 2026
Psychedelics And The Executive Order: From Schedule I To Treatment Priority
Article
29 Jan 2026
Digital Health Policy: FDA Relaxes Restrictions Over Wearables And AI Decision Making Tools In Two New 2026 Guidances
Article
13 Nov 2025
FDA Considers Drug Pricing: Leadership Cites Consumer Cost As A Driver For Changes To Biosimilar Recommendations
Article
15 Oct 2025
FDCA: Fifth Circuit End-Run Suggests State Law Private Right Of Action
Article
16 Sep 2025
FDA On The Offense! Targeting Pharmaceutical Company Drug Advertising In Wave Of Enforcement Actions
Article
13 Aug 2025
FDA Calls For Stronger Industry Collaboration On Infant And Child Food Recalls
Article
09 Jun 2025
GLP-1 Compounded Medications Targeted By Connecticut Attorney General
Article
05 Apr 2025
Texas Court Vacates FDA's Laboratory Developed Test (LDT) Final Rule
Article
19 Mar 2025
Compounded GLP-1 Drugs: Texas Judge Denies PI Motion And Request For Stay Of FDA's Declaration That Tirzepatide Shortage Is Resolved; Plaintiff OFA Appeals
Article
20 Jan 2025
AI Drug Development: FDA Releases Draft Guidance
Article
09 Jan 2025
AI-Enabled Device Software Functions: FDA's Final Guidance For Predetermined Change Control Plans
Article
02 Jan 2025
GLP-1 Drugs: FDA "Re-Confirms" Decision Removing Tirzepatide From The Drug Shortage List
Article
27 Dec 2024
FDA Targets GLP-1 Providers With Warning Letters
Article
17 Dec 2024
Antibody Drug Conjugates Keep Growing: What You Need To Know
Article
03 Dec 2024
GLP-1 Drugs: Brand Companies Push FDA To Limit Compounding
Article
25 Oct 2024
GLP-1 Drugs: FDA Sued Over Removing Tirzepatide From The Drug Shortage List
Article
09 Oct 2024
GLP-1 Drugs: FDA Removes Lilly's Zepbound® And Mounjaro® (Tirzepatide Injection) From Its Drug Shortage List
Article
21 May 2024
The Laws Of Fashion: What's Trending In 2024
